Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00841373 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease
A Phase 1 study of Retinal Ischemia, sponsored by Southern New England Retina Associates.
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT00841373 is a Phase 1 study of Retinal Ischemia that has completed, run by Southern New England Retina Associates. The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00841373, a Phase 1 study of Retinal Ischemia, has completed, sponsored by Southern New England Retina Associates.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.
Conditions Studied
Interventions
- PROCEDURE Panretinal Photocoagulation
- PROCEDURE Panretinal Photocoagulation and intravitreal injection of ranibizumab
Study Locations (1)
Rhode Island
- Southern New England Retina Associates - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2007-07 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00841373
The ClinicalTrials.gov registry entry for NCT00841373 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Southern New England Retina Associates, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinal Ischemia appearing as the primary indexed condition, and to 2 interventions - of which Panretinal Photocoagulation is the first listed.
NCT00841373 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT00841373 about?
NCT00841373 is a clinical study titled "Ranibizumab Supplementing Panretinal Photocoagulation as Treatment for Iris/Angle Neovascularization in Retinal Ischemic Disease". The object of the study is to compare treatment of iris/angle neovascularization with panretinal photocoagulation (laser) to treatment with panretinal photocoagulation and an anti-angiogenic drug: ranibizumab.
What is the current status of trial NCT00841373?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2007-07. Estimated completion is 2010-01.
What conditions does trial NCT00841373 study?
This clinical trial studies the following conditions: Retinal Ischemia.
What interventions are being tested in trial NCT00841373?
The interventions under investigation include: Panretinal Photocoagulation (PROCEDURE), Panretinal Photocoagulation and intravitreal injection of ranibizumab (PROCEDURE).
Who is sponsoring clinical trial NCT00841373?
This trial is sponsored by Southern New England Retina Associates, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00841373 being conducted?
This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.